Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Japanese Subjects With Palmoplantar Pustulosis (JumPPP)
NCT04451720Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in palmoplantar pustulosis (PPP), sponsored by AbbVie Inc.. Started Jul 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04451720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451720.